Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Financial Results Approval

Audit Opinion:

Clean (Unqualified) - The limited review report issued by statutory auditors Rattan Kaur & Associates contains no qualifications or modifications.

Key Financial Highlights [Rs. in Lakhs]:

Standalone Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹23,489.06 (YoY: +50% from ₹15,643.33 in Q2 FY26)
  • Total Income: ₹24,248.91
  • Net Profit: ₹3,102.82 (YoY: +254% from ₹875.69 in Q2 FY26)
  • EPS: ₹3.57 (Basic, not annualized)

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹42,097.28
  • Total Income: ₹43,619.97
  • Net Profit: ₹5,547.22
  • EPS: ₹6.38 (Basic, not annualized)

Balance Sheet Position (as of September 30, 2026):

  • Cash and Cash Equivalents: ₹32,281.43
  • Total Debt: ₹1,514.45 (Non-current borrowings) + ₹433.91 (Current borrowings) = ₹1,948.36
  • Other Equity: ₹1,37,362.49
  • Total Assets: ₹1,75,428.51

Consolidated Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹24,046.35 (YoY: +52% from ₹15,864.01 in Q2 FY26)
  • Total Income: ₹24,806.28
  • Net Profit: ₹3,422.25 (YoY: +328% from ₹799.03 in Q2 FY26)
  • EPS: ₹3.94 (Basic, not annualized)

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹43,191.75
  • Total Income: ₹44,716.87
  • Net Profit: ₹5,890.68
  • EPS: ₹6.77 (Basic, not annualized)

Balance Sheet Position (as of September 30, 2026):

  • Cash and Cash Equivalents: ₹34,035.47
  • Total Debt: ₹1,521.20 (Non-current borrowings) + ₹433.91 (Current borrowings) = ₹1,955.11
  • Other Equity: ₹1,38,742.35
  • Total Assets: ₹1,77,121.75

Segment-wise Performance:

The Company is exclusively in the Pharmaceutical Business segment.

Corporate Actions:

Not Specified

Other Significant Information:

  • Exceptional items for Q2 FY27: ₹57.97 lakhs (balances written back/written off net on account of amounts no longer payable/receivable)
  • The Company has invested surplus funds in various investment avenues monitored by the Investment Committee
  • EBITDA achievement: ₹42.33 crores for Q2 FY27 compared to ₹8.55 crores in Q2 FY26
  • Entities included in consolidation: Ind-Swift Laboratories Limited (parent) and 6 subsidiaries/joint ventures
  • Previous period figures have been re-grouped and re-classified where necessary

Notes:

  • The figures for the quarter ended March 31, 2026 were balancing figures between audited full-year figures and year-to-date figures up to the third quarter of previous financial year
  • The consolidated results include subsidiaries and joint ventures with varying levels of materiality to the group
  • The company has manufacturing facilities in Punjab and Jammu & Kashmir